Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KYMBERLY BROOKE MOYER

Allopathic & Osteopathic Physicians Family Medicine

NPI
1295199933
CMS profile
4218244
Location
GALLATIN, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$2,959.97

11 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $2,350.91 8
Food and Beverage $609.06 3

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
ModernaTX, Inc. $2,959.97 11

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KYMBERLY BROOKE MOYER

NPI 1295199933 · CMS profile ID 4218244

Allopathic & Osteopathic Physicians / Family Medicine

GALLATIN, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1295199933?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KYMBERLY BROOKE MOYER, NPI 1295199933, CMS profile ID 4218244. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1295199933?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). KYMBERLY BROOKE MOYER, NPI 1295199933, CMS profile ID 4218244. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1295199933?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
KYMBERLY BROOKE MOYER, NPI 1295199933, CMS profile ID 4218244, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1295199933?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

11 matching records · $2,959.97 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 11 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–11 of 11.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ModernaTX, Inc. $28.6009/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981405 CMS
ModernaTX, Inc. $36.0009/19/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981449 CMS
ModernaTX, Inc. $255.4609/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981397 CMS
ModernaTX, Inc. $323.5009/09/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981433 CMS
ModernaTX, Inc. $272.9609/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981417 CMS
ModernaTX, Inc. $214.6209/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981425 CMS
ModernaTX, Inc. $895.7907/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981325 CMS
ModernaTX, Inc. $150.0007/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981341 CMS
ModernaTX, Inc. $297.7207/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981353 CMS
ModernaTX, Inc. $325.0007/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981373 CMS
ModernaTX, Inc. $160.3207/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981385 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2023 $2,959.97 11
PY2024 $87.60 4
PY2025 $179.85 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $704,529.61 86
PY2024 Recipient $12,465.00 2
PY2024 Principal investigator $2,124,816.60 102
PY2023 Principal investigator $2,430,274.77 2,115
PY2022 Principal investigator $630,109.32 1,010

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

1,010 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596935
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596937
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596939
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596941
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597031
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597033
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597035
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597037
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597039
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597041
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597043
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597045
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597047
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597049
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597051
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597053
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597055
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597057
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597059
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597061
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597063
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597065
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597067
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597069
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597071
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597303
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597305
Principal investigator 1 ModernaTX, Inc. $986.54 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597307
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597309
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597311
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597313
Principal investigator 1 ModernaTX, Inc. $1,805.28 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597315
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597317
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597319
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597321
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597331
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597333
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597335
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597337
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597339
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597341
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597343
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597345
Principal investigator 1 ModernaTX, Inc. $3,616.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597347
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597501
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597503
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597505
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597507
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597509
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597511
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597513
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597515
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597517
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597519
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597521
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597523
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597525
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597527
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597529
Principal investigator 1 ModernaTX, Inc. $1,805.28 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597531
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597533
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597535
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597537
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597539
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597541
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597543
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597545
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597547
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597769
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597771
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597773
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597775
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597777
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597779
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597781
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597783
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597785
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597787
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597789
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597791
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597793
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597795
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597797
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597799
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963597801
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598017
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598019
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598021
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598023
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598277
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598279
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598281
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598283
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598285
Principal investigator 1 ModernaTX, Inc. $3,616.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598313
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598315
Principal investigator 1 ModernaTX, Inc. $1,805.28 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598317
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598319
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598321
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598323
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598325
Principal investigator 1 ModernaTX, Inc. $1,805.28 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598327
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598329
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598331
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598333
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598335
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598337
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598339
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598341
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598343
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598345
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598347
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598349
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598351
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598353
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598497
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598499
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598571
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598573
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598575
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598577
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598579
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598581
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598583
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598585
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598587
Principal investigator 1 ModernaTX, Inc. $986.54 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598589
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598591
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598593
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598595
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598597
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598599
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598601
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598603
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598605
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598607
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598609
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598611
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598613
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598615
Principal investigator 1 ModernaTX, Inc. $1,805.28 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598803
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598805
Principal investigator 1 ModernaTX, Inc. $1,805.28 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598807
Principal investigator 1 ModernaTX, Inc. $986.54 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598809
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598811
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598813
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598815
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598817
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598819
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598821
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598823
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598825
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598827
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598829
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598831
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598833
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598835
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598837
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598839
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598841
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598843
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963598845
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599061
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599063
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599065
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599067
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599069
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599071
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599073
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599075
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599077
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599079
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599081
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599083
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599085
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599087
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599089
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599091
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599093
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599095
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599097
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599099
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599101
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599103
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599105
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599107
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599109
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599111
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599113
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599167
Principal investigator 1 ModernaTX, Inc. $1,805.28 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599169
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599171
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599173
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599175
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599177
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599179
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599181
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599183
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599185
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599187
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599189
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599191
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599193
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599195
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599197
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599199
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599201
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599203
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599403
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599405
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599461
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599463
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599465
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599467
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599469
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599471
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963599473
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963600077
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963600083
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963600088
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963600093
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963600099
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963600105
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963600109
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963600115
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963600121
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963600125
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963600131
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963600137
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963600143
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963600149
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963600153
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963600159
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963600301
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963600307
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963600313
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963600317
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963600323
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963600329
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963600335
Principal investigator 1 ModernaTX, Inc. $1,805.28 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963600341
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963600345
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963600351
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963600357
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963600363
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963600369
Principal investigator 1 ModernaTX, Inc. $986.54 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963600373
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963600379
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963600385
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601189
Principal investigator 1 ModernaTX, Inc. $1,805.28 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601195
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601201
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601207
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601213
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601217
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601223
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601229
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601235
Principal investigator 1 ModernaTX, Inc. $1,805.28 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601239
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601245
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601251
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601257
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601265
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601329
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601334
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601855
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601857
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601859
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601861
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601863
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601865
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601867
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601869
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601871
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601873
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601917
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601919
Principal investigator 1 ModernaTX, Inc. $1,805.28 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601921
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601923
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601925
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601927
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601929
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601931
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601933
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601935
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601937
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601939
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601941
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601943
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601945
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963601947
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602153
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602155
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602157
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602159
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602161
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602163
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602165
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602167
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602169
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602171
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602173
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602175
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602177
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602179
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602181
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602183
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602185
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602187
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602189
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602191
Principal investigator 1 ModernaTX, Inc. $3,616.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602193
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602195
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602197
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602199
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602201
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602391
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602393
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602395
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602397
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602399
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602401
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602403
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602405
Principal investigator 1 ModernaTX, Inc. $1,805.28 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602407
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602409
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602411
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602413
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602415
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602417
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602419
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602421
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602423
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602425
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602427
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602429
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602431
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602433
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602435
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602437
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602439
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602441
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602645
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602647
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602649
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602651
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602653
Principal investigator 1 ModernaTX, Inc. $1,805.28 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602655
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602657
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602659
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602661
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602663
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602665
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602667
Principal investigator 1 ModernaTX, Inc. $1,805.28 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602669
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602671
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602887
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602889
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602891
Principal investigator 1 ModernaTX, Inc. $1,805.28 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602893
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602895
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602897
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602899
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602901
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602903
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602905
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602907
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602909
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963602911
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603127
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603129
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603131
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603133
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603135
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603137
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603139
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603141
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603143
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603145
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603147
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603149
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603151
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603153
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603155
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603157
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603159
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603161
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603163
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603165
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603167
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603169
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603171
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603373
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603375
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603377
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603379
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603381
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603383
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603385
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603387
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603389
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603391
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603393
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603395
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603397
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603399
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603401
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603403
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603405
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603407
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603409
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603411
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603589
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603591
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603593
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603595
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603597
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603599
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603601
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603603
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603605
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603607
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603609
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603611
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603613
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603615
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603617
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603619
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603621
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603623
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603625
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603627
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603629
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603631
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603633
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603635
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603637
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603881
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603883
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603885
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603887
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603889
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603891
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603893
Principal investigator 1 ModernaTX, Inc. $1,805.28 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603895
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603897
Principal investigator 1 ModernaTX, Inc. $1,805.28 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603899
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603901
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603903
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603905
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603907
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603909
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603911
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603913
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603915
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603917
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963603919
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604097
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604099
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604101
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604103
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604105
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604107
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604109
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604111
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604113
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604115
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604117
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604119
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604121
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604123
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604125
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604127
Principal investigator 1 ModernaTX, Inc. $1,805.28 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604129
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604131
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604133
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604135
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604137
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604139
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604141
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604143
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604145
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604147
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604149
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604151
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604153
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604389
Principal investigator 1 ModernaTX, Inc. $1,805.28 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604391
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604393
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604395
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604397
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604399
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604401
Principal investigator 1 ModernaTX, Inc. $1,805.28 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604403
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604405
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604407
Principal investigator 1 ModernaTX, Inc. $1,805.28 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604409
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604411
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604413
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604415
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604417
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604419
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604421
Principal investigator 1 ModernaTX, Inc. $1,805.28 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604423
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604425
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604427
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604429
Principal investigator 1 ModernaTX, Inc. $1,805.28 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604431
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604433
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604619
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604621
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604623
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604625
Principal investigator 1 ModernaTX, Inc. $1,805.28 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604627
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604629
Principal investigator 1 ModernaTX, Inc. $1,805.28 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604631
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604633
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604635
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604637
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604639
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604641
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604643
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604645
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604647
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604649
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604651
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604653
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604655
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604657
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604659
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604661
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604663
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604665
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604667
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604669
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604835
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604837
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604839
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604841
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604843
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604845
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604847
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604849
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604851
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604853
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604855
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604857
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604859
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604861
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604863
Principal investigator 1 ModernaTX, Inc. $1,805.28 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604865
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604867
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604869
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604871
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604873
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604875
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604877
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604879
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963604881
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605087
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605089
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605091
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605093
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605095
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605097
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605099
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605101
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605103
Principal investigator 1 ModernaTX, Inc. $1,805.28 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605105
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605107
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605109
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605111
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605329
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605331
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605333
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605335
Principal investigator 1 ModernaTX, Inc. $1,805.28 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605337
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605339
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605341
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605343
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605345
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605347
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605349
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605351
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605563
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605565
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605567
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605569
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605571
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605573
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605575
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605577
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605579
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605581
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605583
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605585
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605587
Principal investigator 1 ModernaTX, Inc. $1,805.28 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605589
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605591
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605593
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605595
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605597
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605599
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605601
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605603
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605605
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605607
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605609
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605611
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605613
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605813
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605815
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605817
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605819
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605821
Principal investigator 1 ModernaTX, Inc. $1,805.28 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605823
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605825
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605827
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605829
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605831
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605833
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605835
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605837
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605839
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605841
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605843
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605845
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605847
Principal investigator 1 ModernaTX, Inc. $3,616.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605849
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605851
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605853
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605855
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605857
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605859
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605861
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605863
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605865
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605867
Principal investigator 1 ModernaTX, Inc. $1,805.28 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605869
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605871
Principal investigator 1 ModernaTX, Inc. $1,805.28 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605873
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605875
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605877
Principal investigator 1 ModernaTX, Inc. $986.54 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605879
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605881
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605883
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605885
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605887
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605889
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605891
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605893
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963605895
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606109
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606153
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606155
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606157
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606159
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606161
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606163
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606165
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606421
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606423
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606425
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606427
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606429
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606431
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606433
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606435
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606437
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606439
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606441
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606443
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606445
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606447
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606449
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606451
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606453
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606455
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606457
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606459
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606461
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606463
Principal investigator 1 ModernaTX, Inc. $1,805.28 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606465
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606467
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606469
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606471
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606495
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606497
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606499
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606501
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606705
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606707
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606709
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606711
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606713
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606715
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606717
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606719
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606721
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606723
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606725
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606727
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606729
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606731
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606733
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606735
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606737
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606739
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606741
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606743
Principal investigator 1 ModernaTX, Inc. $874.34 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606745
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606747
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606749
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606751
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606753
Principal investigator 1 ModernaTX, Inc. $1,805.28 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606755
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606757
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606759
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606761
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606763
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606765
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606767
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606987
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606989
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606991
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606993
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606995
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606997
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963606999
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963607001
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963607003
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963607005
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963607007
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963607009
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963607225
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963607227
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963607229
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963607231
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963607233
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963607235
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963607237
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963607239
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963607241
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963607243
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963607245
Principal investigator 1 ModernaTX, Inc. $975.42 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963607247
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963607249
Principal investigator 1 ModernaTX, Inc. $12.64 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963607251
Principal investigator 1 ModernaTX, Inc. $1,805.28 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963607253
Principal investigator 1 ModernaTX, Inc. $2,659.41 12/19/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963607255
Principal investigator 1 ModernaTX, Inc. $300.00 11/28/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593587
Principal investigator 1 ModernaTX, Inc. $300.00 11/28/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593729
Principal investigator 1 ModernaTX, Inc. $300.00 11/28/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594115
Principal investigator 1 ModernaTX, Inc. $40.00 11/28/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594135
Principal investigator 1 ModernaTX, Inc. $100.00 11/28/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594337
Principal investigator 1 ModernaTX, Inc. $100.00 11/28/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594339
Principal investigator 1 ModernaTX, Inc. $40.00 11/28/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595401
Principal investigator 1 ModernaTX, Inc. $40.00 11/28/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595873
Principal investigator 1 ModernaTX, Inc. $100.00 11/28/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595955
Principal investigator 1 ModernaTX, Inc. $40.00 11/28/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595957
Principal investigator 1 ModernaTX, Inc. $100.00 11/28/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596331
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963591997
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592211
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592213
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592281
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592283
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592285
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592287
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592289
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592291
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592345
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592347
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592401
Principal investigator 1 ModernaTX, Inc. $975.42 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592509
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592563
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592565
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592567
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592569
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592571
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592573
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592633
Principal investigator 1 ModernaTX, Inc. $975.42 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592647
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592749
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592751
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592839
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592977
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593031
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593095
Principal investigator 1 ModernaTX, Inc. $975.42 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593097
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593099
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593101
Principal investigator 1 ModernaTX, Inc. $975.42 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593121
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593123
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593205
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593207
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593209
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593311
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593313
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593315
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593413
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593415
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593417
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593493
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593495
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593497
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593567
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593569
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593611
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593613
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593615
Principal investigator 1 ModernaTX, Inc. $975.42 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593617
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593619
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593651
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593733
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593735
Principal investigator 1 ModernaTX, Inc. $975.42 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593737
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593739
Principal investigator 1 ModernaTX, Inc. $975.42 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593741
Principal investigator 1 ModernaTX, Inc. $975.42 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593831
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593833
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593947
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593949
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593951
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594085
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594163
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594165
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594167
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594169
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594205
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594207
Principal investigator 1 ModernaTX, Inc. $975.42 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594209
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594211
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594213
Principal investigator 1 ModernaTX, Inc. $975.42 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594215
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594265
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594267
Principal investigator 1 ModernaTX, Inc. $975.42 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594455
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594457
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594459
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594491
Principal investigator 1 ModernaTX, Inc. $975.42 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594593
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594595
Principal investigator 1 ModernaTX, Inc. $975.42 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594597
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594599
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594645
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594647
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594649
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594651
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594691
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594693
Principal investigator 1 ModernaTX, Inc. $975.42 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594753
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594755
Principal investigator 1 ModernaTX, Inc. $975.42 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594757
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594759
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594785
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594787
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595015
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595017
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595019
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595055
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595057
Principal investigator 1 ModernaTX, Inc. $975.42 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595135
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595137
Principal investigator 1 ModernaTX, Inc. $975.42 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595139
Principal investigator 1 ModernaTX, Inc. $975.42 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595141
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595211
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595213
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595215
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595217
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595265
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595427
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595429
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595499
Principal investigator 1 ModernaTX, Inc. $975.42 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595535
Principal investigator 1 ModernaTX, Inc. $975.42 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595631
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595743
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595745
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595747
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595849
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595851
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595853
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595907
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595909
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595911
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595913
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596035
Principal investigator 1 ModernaTX, Inc. $975.42 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596037
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596039
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596041
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596095
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596097
Principal investigator 1 ModernaTX, Inc. $975.42 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596099
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596187
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596221
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596297
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596299
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596301
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596425
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596427
Principal investigator 1 ModernaTX, Inc. $975.42 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596519
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596641
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596643
Principal investigator 1 ModernaTX, Inc. $975.42 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596645
Principal investigator 1 ModernaTX, Inc. $12.64 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596677
Principal investigator 1 ModernaTX, Inc. $975.42 11/17/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596867
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592257
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592259
Principal investigator 1 ModernaTX, Inc. $12.64 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592357
Principal investigator 1 ModernaTX, Inc. $12.64 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592359
Principal investigator 1 ModernaTX, Inc. $2,659.41 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592381
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592383
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592611
Principal investigator 1 ModernaTX, Inc. $12.64 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592613
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592615
Principal investigator 1 ModernaTX, Inc. $2,659.41 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592617
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592693
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592695
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592723
Principal investigator 1 ModernaTX, Inc. $12.64 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592725
Principal investigator 1 ModernaTX, Inc. $12.64 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592727
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592783
Principal investigator 1 ModernaTX, Inc. $12.64 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592825
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592903
Principal investigator 1 ModernaTX, Inc. $12.64 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592905
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592907
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963592959
Principal investigator 1 ModernaTX, Inc. $2,659.41 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593003
Principal investigator 1 ModernaTX, Inc. $12.64 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593005
Principal investigator 1 ModernaTX, Inc. $12.64 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593109
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593111
Principal investigator 1 ModernaTX, Inc. $12.64 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593277
Principal investigator 1 ModernaTX, Inc. $12.64 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593337
Principal investigator 1 ModernaTX, Inc. $2,659.41 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593339
Principal investigator 1 ModernaTX, Inc. $2,659.41 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593387
Principal investigator 1 ModernaTX, Inc. $12.64 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593463
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593465
Principal investigator 1 ModernaTX, Inc. $12.64 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593467
Principal investigator 1 ModernaTX, Inc. $2,659.41 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593549
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593595
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593597
Principal investigator 1 ModernaTX, Inc. $2,659.41 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593783
Principal investigator 1 ModernaTX, Inc. $2,659.41 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593877
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593921
Principal investigator 1 ModernaTX, Inc. $12.64 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593923
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963593997
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594071
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594139
Principal investigator 1 ModernaTX, Inc. $12.64 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594141
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594341
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594343
Principal investigator 1 ModernaTX, Inc. $2,659.41 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594419
Principal investigator 1 ModernaTX, Inc. $12.64 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594467
Principal investigator 1 ModernaTX, Inc. $12.64 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594469
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594571
Principal investigator 1 ModernaTX, Inc. $12.64 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594573
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594921
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594923
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594925
Principal investigator 1 ModernaTX, Inc. $2,659.41 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594927
Principal investigator 1 ModernaTX, Inc. $2,659.41 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594941
Principal investigator 1 ModernaTX, Inc. $2,659.41 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594943
Principal investigator 1 ModernaTX, Inc. $2,659.41 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594999
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595113
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595115
Principal investigator 1 ModernaTX, Inc. $2,659.41 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595189
Principal investigator 1 ModernaTX, Inc. $12.64 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595319
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595321
Principal investigator 1 ModernaTX, Inc. $12.64 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595323
Principal investigator 1 ModernaTX, Inc. $12.64 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595473
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595475
Principal investigator 1 ModernaTX, Inc. $12.64 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595601
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595603
Principal investigator 1 ModernaTX, Inc. $2,659.41 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595615
Principal investigator 1 ModernaTX, Inc. $2,659.41 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595677
Principal investigator 1 ModernaTX, Inc. $12.64 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595679
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595681
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595685
Principal investigator 1 ModernaTX, Inc. $2,659.41 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595839
Principal investigator 1 ModernaTX, Inc. $12.64 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595879
Principal investigator 1 ModernaTX, Inc. $2,659.41 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595881
Principal investigator 1 ModernaTX, Inc. $12.64 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596161
Principal investigator 1 ModernaTX, Inc. $2,659.41 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596163
Principal investigator 1 ModernaTX, Inc. $12.64 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596165
Principal investigator 1 ModernaTX, Inc. $12.64 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596201
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596263
Principal investigator 1 ModernaTX, Inc. $2,659.41 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596269
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596271
Principal investigator 1 ModernaTX, Inc. $2,659.41 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596273
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596339
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596341
Principal investigator 1 ModernaTX, Inc. $2,659.41 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596343
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596403
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596405
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596503
Principal investigator 1 ModernaTX, Inc. $2,659.41 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596505
Principal investigator 1 ModernaTX, Inc. $12.64 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596605
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596607
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596609
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596611
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596613
Principal investigator 1 ModernaTX, Inc. $2,659.41 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596615
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596807
Principal investigator 1 ModernaTX, Inc. $1,805.28 11/14/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596921
Principal investigator 1 ModernaTX, Inc. $1,000.00 10/31/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594493
Principal investigator 1 ModernaTX, Inc. $2,000.00 10/31/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963594995
Principal investigator 1 ModernaTX, Inc. $800.00 10/31/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595105
Principal investigator 1 ModernaTX, Inc. $1,500.00 10/31/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963595585
Principal investigator 1 ModernaTX, Inc. $10,000.00 10/31/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963596501
Principal investigator 1 ModernaTX, Inc. $18.00 10/07/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963292663
Principal investigator 1 ModernaTX, Inc. $498.00 09/12/2022 Non-covered Recipient Entity
DELRICHT RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963292631